title: Effects of uric acid levels on outcome in severe ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator.
abstract: Uric acid (UA) has been known to be a neuroprotective antioxidant because of its free radical scavenger activity. We studied the influence of UA in patients with acute ischemic stroke after thrombolytic therapy. Two hundred eighteen consecutive patients treated with intravenous thrombolysis were included in this analysis. We analyzed the relationship between serum UA levels obtained at the emergency department and clinical outcomes. Early improvement and excellent functional outcomes were measured using the National Institutes of Health Stroke Scale (NIHSS) 24 h after onset and the modified Rankin scale after 3 months. There was no significant relationship between serum UA levels and early improvement or excellent functional outcome in the total patients (p = 0.583 and p = 0.082, respectively). However, in patients with severe baseline stroke deficits (NIHSS score ≥15), higher-tertile UA levels were significantly associated with excellent functional outcomes (p = 0.003). Excellent functional outcomes in patients with severe baseline disability might have a significant association with serum UA levels particularly in men but not in women (p = 0.007 in men and p = 0.621 in women). Increased serum UA levels might be associated with better outcomes in ischemic stroke patients treated with intravenous thrombolysis, but the effectiveness of UA can differ by initial stroke severity and gender.
authors.affiliation: Department of Neurology, College of Medicine, Kyung Hee University, Seoul, Korea.
authors.forename: Sang-Hwa
authors.initials: SH
authors.lastname: Lee
authors.forename: Sung Hyuk
authors.initials: SH
authors.lastname: Heo
authors.forename: Jun-Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Dokyung
authors.initials: D
authors.lastname: Lee
authors.forename: Ji Sung
authors.initials: JS
authors.lastname: Lee
authors.forename: Young Seo
authors.initials: YS
authors.lastname: Kim
authors.forename: Hyun Young
authors.initials: HY
authors.lastname: Kim
authors.forename: Seong-Ho
authors.initials: SH
authors.lastname: Koh
authors.forename: Dae-Il
authors.initials: DI
authors.lastname: Chang
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function; D020521:Stroke / Q000097:blood / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
chemical_list: D005343:Fibrinolytic Agents; D014527:Uric Acid; D010959:Tissue Plasminogen Activator